Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

Drug rashes can be an unwanted side effect of many medications. Learn which medications can cause these skin reactions.

American Century Companies Inc. increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 3.5% in ...

Deucrictibant is designed to block the effects of bradykinin, which is responsible for angioedema attacks. With a current ratio of 19.08, InvestingPro analysis shows the company has ample ...

The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.

Hair dyes can be an exciting way to refresh your look, but understanding their risks ensures you make informed beauty choices ...

Brandi Glanville said she's getting more support from social media users than from doctors as she navigates facial ...

Pharvaris (PHVS) announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, for the ...

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...